An oral, brain penetrant EGFR mutant inhibitor with exquisite selectivity, a drug that was originally developed from a brain cholesterol metabolite, and a muscarinic antagonist and β2 agonist that was developed using soft drug design are some examples of this month's MOTM. In the slide deck, you'll also find a drug utilizing an N-oxide motif and a drug optimized to overcome aldehyde oxidase metabolism. Check out the ten molecule minireviews in the slide deck which covers:
Where are all of the Molecules of the Month in clinical development?
What's known about differentiation from previous molecules?
Where did the starting points come from?
Industry context, mechanism of action details, and more…
